FGFR2

Chr 10AD

fibroblast growth factor receptor 2

Also known as: BBDS, BEK, BFR-1, CD332, CEK3, CFD1, ECT1, JWS

The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jan 2009]

Primary Disease Associations & Inheritance

?Scaphocephaly, maxillary retrusion, and impaired intellectual developmentMIM #609579
Antley-Bixler syndrome without genital anomalies or disordered steroidogenesisMIM #207410
AD
Apert syndromeMIM #101200
AD
Beare-Stevenson cutis gyrata syndromeMIM #123790
AD
Bent bone dysplasia syndromeMIM #614592
AD
Craniofacial-skeletal-dermatologic dysplasiaMIM #101600
AD
Craniosynostosis, nonspecific
Crouzon syndromeMIM #123500
AD
Gastric cancer, somaticMIM #613659
Jackson-Weiss syndromeMIM #123150
AD
LADD syndrome 1MIM #149730
AD
Pfeiffer syndromeMIM #101600
AD
Saethre-Chotzen syndromeMIM #101400
AD
Scaphocephaly and Axenfeld-Rieger anomaly
UniProtFamilial scaphocephaly syndrome
UniProtLacrimo-auriculo-dento-digital syndrome 1
478
ClinVar variants
50
Pathogenic / LP
1.00
pLI score· haploinsufficient
12
Active trials
Clinical SummaryFGFR2
🧬
Gene-Disease Validity (ClinGen)
Apert syndrome · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

6 total gene-disease associations curated

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
50 Pathogenic / Likely Pathogenic· 243 VUS of 478 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.27LOEUF
pLI 0.997
Z-score 5.29
OE 0.14 (0.070.27)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
2.40Z-score
OE missense 0.69 (0.630.75)
323 obs / 469.5 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.14 (0.070.27)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.69 (0.630.75)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.11
01.21.6
LoF obs/exp: 6 / 43.8Missense obs/exp: 323 / 469.5Syn Z: -1.17

ClinVar Variant Classifications

478 submitted variants in ClinVar

Classification Summary

Pathogenic30
Likely Pathogenic20
VUS243
Likely Benign142
Benign21
Conflicting22
30
Pathogenic
20
Likely Pathogenic
243
VUS
142
Likely Benign
21
Benign
22
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
4
12
14
0
30
Likely Pathogenic
1
14
5
0
20
VUS
3
196
33
11
243
Likely Benign
0
6
57
79
142
Benign
0
0
21
0
21
Conflicting
22
Total822813090478

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

FGFR2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

FGFR2-related lacrimo-auriculo-dento-digital syndrome (LADD)

definitive
ADGain Of FunctionAltered Gene Product Structure, Uncertain
Dev. DisordersSkinSkeletal
G2P ↗
missense variantinframe deletioninframe insertion

FGFR2-related Beare-Stevenson cutis gyrata syndrome

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkinSkeletal
G2P ↗

FGFR2-related Jackson-Weiss syndrome

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkin
G2P ↗

FGFR2-related Antley-Bixler syndrome

strong
ADUndeterminedAltered Gene Product Structure
Dev. Disorders
G2P ↗
missense variantinframe deletioninframe insertion

FGFR2-related Crouzon syndrome

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkinSkeletal
G2P ↗

FGFR2-related Apert Syndrome

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkinSkeletal
G2P ↗

FGFR2-related Pfeiffer syndrome

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkinSkeletal
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

?Scaphocephaly, maxillary retrusion, and impaired intellectual development

MIM #609579

Molecular basis of disorder known

Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis

MIM #207410

Molecular basis of disorder known

Autosomal dominant

Apert syndrome

MIM #101200

Molecular basis of disorder known

Autosomal dominant

Beare-Stevenson cutis gyrata syndrome

MIM #123790

Molecular basis of disorder known

Autosomal dominant

Bent bone dysplasia syndrome

MIM #614592

Molecular basis of disorder known

Autosomal dominant

Craniofacial-skeletal-dermatologic dysplasia

MIM #101600

Molecular basis of disorder known

Autosomal dominant

Craniosynostosis, nonspecific

Molecular basis of disorder known

Crouzon syndrome

MIM #123500

Molecular basis of disorder known

Autosomal dominant

Gastric cancer, somatic

MIM #613659

Molecular basis of disorder known

Jackson-Weiss syndrome

MIM #123150

Molecular basis of disorder known

Autosomal dominant

LADD syndrome 1

MIM #149730

Molecular basis of disorder known

Autosomal dominant

Pfeiffer syndrome

MIM #101600

Molecular basis of disorder known

Autosomal dominant

Saethre-Chotzen syndrome

MIM #101400

Molecular basis of disorder known

Autosomal dominant

Scaphocephaly and Axenfeld-Rieger anomaly

Molecular basis of disorder known

📖
GeneReview available — FGFR2
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Locally Advanced CholangiocarcinomaIntrahepatic CholangiocarcinomaSolid Tumor

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

RECRUITING
NCT06160752Phase PHASE1Tyra Biosciences, IncStarted 2023-11-22
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cyclesPhase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Gastric CancerHealthy

Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer

RECRUITING
NCT05991947Zhejiang Cancer HospitalStarted 2021-03-01
No intervention
Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, Adult

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

RECRUITING
NCT06777316Phase PHASE1, PHASE2Cogent Biosciences, Inc.Started 2025-01-22
CGT4859
Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

RECRUITING
NCT06728410Phase PHASE2Mehmet AkceStarted 2026-01-27
PemigatinibDurvalumab
Rare Malignant Neoplasm

Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia

RECRUITING
NCT05217407National Cancer Center, JapanStarted 2021-11-30
Genomic sequence
HER2-Gastric/Gastroesophageal Junction CancerUrothelial CarcinomaNon-Small Cell Lung Cancer

A Phase 2 Clinical Study of ABSK061 and ABSK043

RECRUITING
NCT06632262Phase PHASE2Abbisko Therapeutics Co, LtdStarted 2024-11-13
ABSK061 + ABSK043ABSK061+ABSK043 in combination with CAPOX
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

ACTIVE NOT RECRUITING
NCT04963153Phase PHASE1National Cancer Institute (NCI)Started 2022-07-07
Biospecimen CollectionBone ScanComputed Tomography
Advanced Solid Tumor

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

ACTIVE NOT RECRUITING
NCT04083976Phase PHASE2Janssen Research & Development, LLCStarted 2019-11-20
Erdafitinib
Cholangiocarcinoma,Adult

Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma

NOT YET RECRUITING
NCT05039892Phase PHASE23D Medicines (Beijing) Co., Ltd.Started 2026-12
3D185
Advanced Pancreatic CarcinomaMetastatic Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

RECRUITING
NCT06906562Phase PHASE2Sameek RoychowdhuryStarted 2025-08-26
PemigatinibComputed Tomography (CT)Magnetic Resonance Imaging
Gastric and Cardia Adenocarcinomas

Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study

RECRUITING
NCT02491840Phase NAUniversity Hospital, Strasbourg, FranceStarted 2016-05
Biopsy
FGFR2 Gene Fusion/RearrangementOther Solid Tumors, Adult

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

NOT YET RECRUITING
NCT07359820Phase PHASE2Elevar TherapeuticsStarted 2026-02
Lirafugratinib